On a per-share basis, the
The results topped
The maker of heart devices posted revenue of
Abiomed expects full-year revenue in the range of
Abiomed shares have increased 12% since the beginning of the year. The stock has dropped 45% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a
Automated Insights, source